In July 2023, the Centers for Medicare & Medicaid services (CMS) overhauled its oncology value-based care model, instituting the Enhancing Oncology Model (EOM) as a replacement for the Oncology Care Model (OCM) that expired in 2022. Only 41 community oncology practices participated in EOM’s first cohort—a significant decrease from the 122 participants under OCM. In response, CMS created a second EOM application round and instituted several reforms to drive participation and improve the model's effectiveness.
The second round of EOM applications closed on September 16, 2024, and came with several enhancements, including:
Thus far, EOM has led to modest changes in participating community oncology practices (Figure 1); in part this is due to many EOM participants implementing changes during their prior experience in OCM.
As the second round of EOM progresses, MAI anticipates additional practices joining the initiative. However, the full scope of patient and provider outcomes remains to be seen.
For deeper insights into EOM’s impact on community oncology practices and manufacturer considerations, explore our 2024 Community Oncology Report.
Please don’t hesitate to reach out if you have any questions, I would love to hear from you! I can be reached at asheth@hmpglobal.com.
As manufacturers prepare for Medicare drug price negotiations, a critical question emerges: How will your provider engagement strategy evolve when Maximum Fair Prices (MFP) take effect in 2026?
Emma BijesseAt HMP Market Access Insights, we’re lucky to have a team of experts dedicated to uncovering meaningful insights in the oncology space. One of those experts is Dan, whose work is shaping how we approach community oncology research.
Daniel BuchenbergerAs IDNs face increasing complexity in oncology management, having a strategic approach backed by actionable insights is critical. Our dataset doesn’t just offer data—it equips your teams with the tools to anticipate challenges and seize opportunities.
Emma Bijesse